Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis

Brain

Volumn 133, Issue 4, 2010, Pages 1082-1093

  Comabella, Manuel ^a   Fernández, Marta ^a   Martin, Roland ^b   Rivera Vallvé, Stephanie ^c   Borrás, Eva ^c   Chiva, Cristina ^c   Juli, Eva ^a   Rovira, Alex ^a   Cantó, Ester ^a   Alvarez Cermeño, Jose Carlos ^d   Villar, Luisa María ^d   Tintoré, Mar ^a   Montalban, Xavier ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITAT POMPEU FABRA   (Spain)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Cerebrospinal fluid; Chitinase 3 like 1; Clinically isolated syndrome; Multiple sclerosis; Proteomics

Indexed keywords

CERULOPLASMIN; CHITINASE; CHITINASE 3 LIKE 1; GADOLINIUM; UNCLASSIFIED DRUG; VITAMIN D BINDING PROTEIN;

ADULT; ARTICLE; BRAIN DAMAGE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; MALE; MASS SPECTROMETRY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEOMICS; VALIDATION STUDY;

EID: 77950854119     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awq035     Document Type: Article

References (48)

1. Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, Polman CH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997; 120: 2059-2069 (Pubitemid 27493740)
2. Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003; 349: 139-145 (Pubitemid 36818783)
3. Boehm AM, Pütz S, Altenhöfer D, Sickmann A, Falk M. Precise protein quantification based on peptide quantification using iTRAQTM. BMC Bioinformatics 2007; 8: 214. (Pubitemid 47225253)
4. Bresnihan B, Gogarty M, FitzGerald O, Dayer JM, Burger D. Apolipoprotein A-I infiltration in rheumatoid arthritis synovial tissue: a control mechanism of cytokine production? Arthritis Res Ther 2004; 6: R563-6.
5. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002; 346: 158-164 (Pubitemid 34438881)
6. Chiasserini D, Di Filippo M, Candeliere A, Susta F, Orvietani PL, Calabresi P, et al. CSF proteome analysis in multiple sclerosis patients by two-dimensional electrophoresis. Eur J Neurol 2008; 15: 998-1001.
7. Comabella M, Domínguez C, Rio J, Martín-Gallán P, Vilches A, Vilarrasa N, et al. Plasma chitotriosidase activity in multiple sclerosis. Clin Immunol 2009; 131: 216-222
8. D'Aguanno S, Barassi A, Lupisella S, d'eril GM, Del Boccio P, Pieragostino D, et al. Differential cerebro spinal fluid proteome investigation of Leber hereditary optic neuropathy (LHON) and multiple sclerosis. J Neuroimmunol 2008; 193: 156-160
9. DeSouza L, Diehl G, Rodrigues MJ, Guo J, Romaschin AD, Colgan TJ, et al. Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cICAT with multidimensional liquid chromatography and tandem mass spectrometry. J Proteome Res 2005; 4: 377-386 (Pubitemid 40548142)
10. Diefenbach CS, Shah Z, Iasonos A, Barakat RR, Levine DA, Aghajanian C, et al. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. Gynecol Oncol 2007; 104: 435-442 (Pubitemid 46156955)
11. Dumont D, Noben JP, Raus J, Stinissen P, Robben J. Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients. Proteomics 2004; 4: 2117-2124 (Pubitemid 38880377)
12. Erzin Y, Uzun H, Karatas A, Celik AF. Serum YKL-40 as a marker of disease activity and stricture formation in patients with Crohn's disease. J Gastroenterol Hepatol 2008; 23: e357-62.
13. Fischer C, Arneth B, Koehler J, Lotz J, Lackner KJ. Kappa free light chains in cerebrospinal fluid as markers of intrathecal immunoglobulin synthesis. Clin Chem 2004; 50: 1809-1813 (Pubitemid 39298010)
14. Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, Lanyon R, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008; 131: 808-817 (Pubitemid 351294716)
15. Gveric D, Herrera B, Petzold A, Lawrence DA, Cuzner ML. Impaired fibrinolysis in multiple sclerosis: a role for tissue plasminogen activator inhibitors. Brain 2003; 126: 1590-1598 (Pubitemid 36834935)
16. Hammack BN, Owens GP, Burgoon MP, Gilden DH. Improved resolution of human cerebrospinal fluid proteins on two-dimensional gels. Mult Scler 2003; 9: 472-475
17. Irani DN, Anderson C, Gundry R, Cotter R, Moore S, Kerr DA, et al. Cleavage of cystatin C in the cerebrospinal fluid of patients with multiple sclerosis. Ann Neurol 2006; 59: 237-247 (Pubitemid 43202476)
18. Jensen BV, Johansen JS, Price PA. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin Cancer Res 2003; 9: 501-512
19. Johansen JS, Stoltenberg M, Hansen M, Florescu A, Hørslev-Petersen K, Lorenzen I, et al. Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology 1999; 38: 618-626 (Pubitemid 29507329)
20. Johansen JS, Drivsholm L, Price PA, Christensen IJ. High serum YKL-40 level in patients with small cell lung cancer is related to early death. Lung Cancer 2004; 46: 333-340 (Pubitemid 39487308)
21. Johansen JS, Milman N, Hansen M, Garbarsch C, Price PA, Graudal N. Increased serum YKL-40 in patients with pulmonary sarcoidosis-a potential marker of disease activity? Respir Med 2005; 99: 396-402. (Pubitemid 40347821)
22. Koutroubakis IE, Petinaki E, Dimoulios P, Vardas E, Roussomoustakaki M, Maniatis AN, et al. Increased serum levels of YKL-40 in patients with inflammatory bowel disease. Int J Colorectal Dis 2003; 18: 254-259 (Pubitemid 36764173)
23. Kucur M, Isman FK, Balci C, Onal B, Hacibekiroglu M, Ozkan F, et al. Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia. Urol Oncol 2008; 26: 47-52.
24. Kuhle J, Pohl C, Mehling M, Edan G, Freedman MS, Hartung HP, et al. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med 2007; 356: 371-378 (Pubitemid 46148779)
25. Lehmensiek V, Süssmuth SD, Tauscher G, Brettschneider J, Felk S, Gillardon F, et al. Cerebrospinal fluid proteome profile in multiple sclerosis. Mult Scler 2007; 13: 840-849 (Pubitemid 351540854)
26. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127
27. Milner R, Crocker SJ, Hung S, Wang X, Frausto RF, del Zoppo GJ. Fibronectin- and vitronectin-induced microglial activation and matrix metalloproteinase-9 expression is mediated by integrins alpha5beta1 and alphavbeta5. J Immunol 2007; 178: 8158-8167
28. Mitsuhashi A, Matsui H, Usui H, Nagai Y, Tate S, Unno Y, et al. Serum YKL-40 as a marker for cervical adenocarcinoma. Ann Oncol 2009; 20: 71-77
29. Niino M, Kikuchi S, Fukazawa T, Yabe I, Tashiro K. No association of vitamin D-binding protein gene polymorphisms in Japanese patients with MULTIPLE SCLEROSIS. J Neuroimmunol 2002; 127: 177-179 (Pubitemid 34603589)
30. Noben JP, Dumont D, Kwasnikowska N, Verhaert P, Somers V, Hupperts R, et al. Lumbar cerebrospinal fluid proteome in multiple sclerosis: characterization by ultrafiltration, liquid chromatography, and mass spectrometry. J Proteome Res 2005; 5: 1647-1657 (Pubitemid 44036138)
31. Pasterkamp RJ, Peschon JJ, Spriggs MK, Kolodkin AL. Semaphorin 7A promotes axon outgrowth through integrins and MAPKs. Nature 2003; 424: 398-405.
32. Pelayo R, Tintoré M, Montalban X, Rovira A, Espejo C, Reindl M, et al. Antimyelin antibodies with no progression to multiple sclerosis. N Engl J Med 2007; 356: 426-428 (Pubitemid 46148809)
33. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-231 (Pubitemid 13158528)
34. Qin Z, Qin Y, Liu S. Alteration of DBP levels in CSF of patients with MULTIPLE SCLEROSIS by proteomics analysis. Cell Mol Neurobiol 2009; 29: 203-210
35. Recklies AD, Ling H, White C, Bernier SM. Inflammatory cytokines induce production of CHI3L1 by articular chondrocytes. J Biol Chem 2005; 280: 41213-41221 (Pubitemid 41832176)
36. Renkema GH, Boot RG, Au FL, Donker-Koopman WE, Strijland A, Muijsers AO, et al. Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem 1998; 251: 504-509 (Pubitemid 28080953)
37. Sotgiu S, Barone R, Arru G, Fois ML, Pugliatti M, Sanna A, et al. Intrathecal chitotriosidase and the outcome of multiple sclerosis. Mult Scler 2006; 12: 551-557 (Pubitemid 46940627)
38. Stoop MP, Dekker LJ, Titulaer MK, Burgers PC, Sillevis Smitt PA, Luider TM, et al. Multiple sclerosis-related proteins identified in cerebrospinal fluid by advanced mass spectrometry. Proteomics 2008; 8: 1576-1585
39. Tintoré M, Rovira A, Río J, Nos C, Grivé E, Té llez N, et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006; 67: 968-972 (Pubitemid 44454586)
40. Tintoré M, Rovira A, Río J, Tur , C , Pelayo R, Nos C, et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology 2008; 70: 1079-1083 (Pubitemid 351464763)
41. Tumani H, Lehmensiek V, Rau D, Guttmann I, Tauscher G, Mogel H, et al. CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis. Neurosci Lett 2009; 452: 214-217
42. van Bilsen JH, van Dongen H, Lard LR, van der Voort EI, Elferink DG, Bakker AM, et al. Functional regulatory immune responses against human cartilage glycoprotein-39 in health vs. proinflammatory responses in rheumatoid arthritis. Proc Natl Acad Sci USA 2004; 101: 17180-17185 (Pubitemid 39627794)
43. Vos K, Steenbakkers P, Miltenburg AM, Bos E, van Den Heuvel MW, van Hogezand RA, et al. Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis 2000; 59: 544-548 (Pubitemid 30445834)
44. Wassif WS, Sherwood RA, Amir A, Idowu B, Summers B, Leigh N, et al. Serum carnosinase activities in central nervous system disorders. Clin Chim Acta 1994; 225: 57-64. (Pubitemid 24118483)
45. Wiese S, Reidegeld KA, Meyer HE, Warscheid B. Protein labelling by iTRAQ: A new tool for quantitative mass spectrometry in proteome research. Proteomics 2007; 7: 340-350 (Pubitemid 46293976)
46. Wu WW, Wang G, Baek SJ, Shen RF. Comparative study of three proteomic quantitative methods, DIGE, cICAT, and iTRAQ, using 2D Gel- or LC-MALDI TOF/TOF. J Proteome Res 2006; 5: 651-658 (Pubitemid 43364106)
47. You JS, Gelfanova V, Knierman MD, Witzmann FA, Wang M, Hale JE. The impact of blood contamination on the proteome of cerebrospinal fluid. Proteomics 2005; 5: 290-296 (Pubitemid 40189659)
48. Zieske LR. A perspective on the use of iTRAQTM reagent technology for protein complex and profiling studies. J Exp Bot 2006; 57: 1501-1508